// App-Quantinova.ai

5075 : Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Howard I. Scher

Principal Investigators

  • Joseph Schonhoft

  • Ryon P Graf

  • Adam Jendrisak

  • Ethan Barnett

  • Anuradha Jayaram

  • Eric Winquist

  • Mark Landers

  • Yipeng Wang

  • Alison L Allan

  • Gerhardt Attard

  • Ryan Dittamore

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Epic Sciences, Inc., San Diego, CA

  • St James Hospital, Kilmainhani, Ireland

  • Western University and London Health Sciences Centre, London, ON, CA

  • London Regional Cancer Program, London Health Sciences Centre, London, ON, Canada

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

Locations

  • United States

  • Ireland

  • United Kingdom

  • Canada

Companies

  • EPIC SCIENCES, INC.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Androgen receptor variant 7

  • Circulating tumor cells

Drug/Treatment

  • Androgen Tear

  • taxane

  • Carbetimer

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved